JP2009523777A5 - - Google Patents

Download PDF

Info

Publication number
JP2009523777A5
JP2009523777A5 JP2008550839A JP2008550839A JP2009523777A5 JP 2009523777 A5 JP2009523777 A5 JP 2009523777A5 JP 2008550839 A JP2008550839 A JP 2008550839A JP 2008550839 A JP2008550839 A JP 2008550839A JP 2009523777 A5 JP2009523777 A5 JP 2009523777A5
Authority
JP
Japan
Prior art keywords
group
deoxyactagardine
alkyl
compound
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008550839A
Other languages
English (en)
Japanese (ja)
Other versions
JP5219837B2 (ja
JP2009523777A (ja
Filing date
Publication date
Priority claimed from GBGB0600928.6A external-priority patent/GB0600928D0/en
Application filed filed Critical
Publication of JP2009523777A publication Critical patent/JP2009523777A/ja
Publication of JP2009523777A5 publication Critical patent/JP2009523777A5/ja
Application granted granted Critical
Publication of JP5219837B2 publication Critical patent/JP5219837B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008550839A 2006-01-17 2007-01-17 A.ガルバジネンシスおよびa.リグリエに由来するランチビオティック生合成遺伝子クラスター Expired - Fee Related JP5219837B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0600928.6A GB0600928D0 (en) 2006-01-17 2006-01-17 Improvements relating to lantibiotics
GB0600928.6 2006-01-17
PCT/GB2007/000138 WO2007083112A2 (en) 2006-01-17 2007-01-17 Lantibiotic biosynthetic gene clusters from a. garbadinensis and a. liguriae

Publications (3)

Publication Number Publication Date
JP2009523777A JP2009523777A (ja) 2009-06-25
JP2009523777A5 true JP2009523777A5 (US07794700-20100914-C00152.png) 2010-03-04
JP5219837B2 JP5219837B2 (ja) 2013-06-26

Family

ID=35998187

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008550839A Expired - Fee Related JP5219837B2 (ja) 2006-01-17 2007-01-17 A.ガルバジネンシスおよびa.リグリエに由来するランチビオティック生合成遺伝子クラスター

Country Status (20)

Country Link
US (3) US7989416B2 (US07794700-20100914-C00152.png)
EP (2) EP2189472A1 (US07794700-20100914-C00152.png)
JP (1) JP5219837B2 (US07794700-20100914-C00152.png)
KR (1) KR101573536B1 (US07794700-20100914-C00152.png)
CN (1) CN101389641B (US07794700-20100914-C00152.png)
AT (1) ATE534659T1 (US07794700-20100914-C00152.png)
AU (1) AU2007206769B2 (US07794700-20100914-C00152.png)
BR (1) BRPI0706525A2 (US07794700-20100914-C00152.png)
CA (1) CA2637315A1 (US07794700-20100914-C00152.png)
CY (1) CY1112559T1 (US07794700-20100914-C00152.png)
DK (1) DK1979375T3 (US07794700-20100914-C00152.png)
ES (1) ES2378090T3 (US07794700-20100914-C00152.png)
GB (1) GB0600928D0 (US07794700-20100914-C00152.png)
IL (1) IL192446A0 (US07794700-20100914-C00152.png)
MX (1) MX2008009047A (US07794700-20100914-C00152.png)
NZ (1) NZ569486A (US07794700-20100914-C00152.png)
PL (1) PL1979375T3 (US07794700-20100914-C00152.png)
PT (1) PT1979375E (US07794700-20100914-C00152.png)
SI (1) SI1979375T1 (US07794700-20100914-C00152.png)
WO (1) WO2007083112A2 (US07794700-20100914-C00152.png)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0600928D0 (en) 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
GB0714030D0 (en) * 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
GB0900599D0 (en) 2009-01-14 2009-02-18 Novacta Biosystems Ltd Treatment
MX2011007313A (es) * 2009-01-14 2011-08-04 Novacta Biosystems Ltd Derivados de desoxiactagardina.
SG173504A1 (en) * 2009-02-04 2011-09-29 Novacta Biosystems Ltd Actagardine derivatives
TW201138800A (en) 2010-02-02 2011-11-16 Novacta Biosystems Ltd Salts
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
MX2013000350A (es) 2010-07-14 2013-03-18 Novacta Biosystems Ltd Formulacion que comprende lantibiotico tipo b.
GB201013509D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013513D0 (en) * 2010-08-11 2010-09-22 Novacta Biosystems Ltd Formulations
GB201013508D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013507D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
US9975930B2 (en) 2012-11-30 2018-05-22 Naicons S.R.L. Lantibiotic derivatives and process for their preparation
CN103483433B (zh) * 2013-09-10 2015-05-27 中国科学院微生物研究所 一种新型高效的羊毛硫细菌素cerecidin及其应用
CN106188253B (zh) * 2016-08-26 2020-08-18 上海交通大学 抗菌肽Lexapeptide及其制备方法和用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
GB8507528D0 (en) 1985-03-22 1985-05-01 Lepetit Spa Basis monocarboxyamide derivatives
US5304540A (en) 1988-06-22 1994-04-19 Applied Microbiology, Inc. Pharmaceutical bacteriocin compositions and methods for using the same
IN167138B (US07794700-20100914-C00152.png) 1988-08-17 1990-09-01 Hoechst India
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
IT1260505B (it) 1992-06-01 1996-04-09 Poli Ind Chimica Spa Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
IL107887A (en) 1992-12-08 2003-07-06 Ambi Inc Stabilized lanthionine containing bacteriocin compositions
US5512269A (en) 1993-06-09 1996-04-30 Burroughs Wellcome, Co. Method of treating retained pulmonary secretions
ATE255165T1 (de) 1994-09-12 2003-12-15 Aventis Pharma Gmbh Rekombinantes mersacidin und verfahren zu seiner herstellung
KR19990028283A (ko) 1995-06-23 1999-04-15 스폰 벤자민 티. 항생제-내성 그람 양성 박테리아의 억제 및 감염 치료 방법
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US5958873A (en) 1997-06-09 1999-09-28 University Of Cincinnati Oral formulation for treatment of bacteria-induced diseases of the colon
US5985823A (en) 1997-06-09 1999-11-16 Ambi Inc. Method for the treatment of diarrheal disease and for eliminating particular bacterial populations from the colon
DE19745583A1 (de) 1997-10-15 1999-04-22 Hoechst Marion Roussel De Gmbh Neues Lantibiotikum verwandt mit Actagardine, Verfahren zur Herstellung und Verwendung derselben
US6569830B1 (en) 1999-03-05 2003-05-27 Ambi, Inc. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
PT1294358E (pt) 2000-06-28 2004-12-31 Smithkline Beecham Plc Processo de moagem por via humida
GB0110432D0 (en) 2001-04-27 2001-06-20 Plant Bioscience Ltd Lantibiotic production
WO2002103010A1 (en) 2001-06-14 2002-12-27 Plant Bioscience Limited Methods and materials for targeted gene disruption in actinomycete bacteria
US6861236B2 (en) 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
US7199230B2 (en) 2002-10-10 2007-04-03 Molichem Medicines, Inc. Nucleic acids encoding duramycin
US7351687B2 (en) 2003-07-18 2008-04-01 Vicuron Pharmaceuticals, Inc. Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof
JP4163737B2 (ja) 2003-07-18 2008-10-08 ヴァイキュロン ファーマシューティカルズ, インコーポレイテッド 抗生物質107891、そのa1因子とa2因子、その薬剤学的に許容される塩、組成物、およびその使用
WO2005079508A2 (en) * 2004-02-17 2005-09-01 Cancervax Corporation Method and composition for angiogenesis inhibition
GB0406870D0 (en) 2004-03-26 2004-04-28 Novacta Biosystems Ltd Improvements relating to the production of lantibiotics
JP2009509519A (ja) 2005-09-27 2009-03-12 ノヴァクタ バイオシステムズ リミティッド ランチビオティックメルサシジンの変種およびそれらの使用
GB0600928D0 (en) 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
KR101170283B1 (ko) 2006-10-27 2012-07-31 화이자 프로덕츠 인코포레이티드 하이드록시프로필 메틸 셀룰로스 경질 캡슐 및 이의 제조 방법
WO2008151434A1 (en) 2007-06-12 2008-12-18 The University Of British Columbia Small cationic antimicrobial peptides
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
CA2742753A1 (en) 2008-11-24 2010-05-27 Sentinella Pharmaceuticals, Inc. ("Sentinella") Lantibiotic carboxyamide derivatives with enhanced antibacterial activity
MX2011007313A (es) 2009-01-14 2011-08-04 Novacta Biosystems Ltd Derivados de desoxiactagardina.
GB0900599D0 (en) 2009-01-14 2009-02-18 Novacta Biosystems Ltd Treatment
SG173504A1 (en) 2009-02-04 2011-09-29 Novacta Biosystems Ltd Actagardine derivatives
EP2216937A1 (en) 2009-02-10 2010-08-11 Alcatel Lucent Alarm notification between customer premises equipment and a remote management server

Similar Documents

Publication Publication Date Title
JP2009523777A5 (US07794700-20100914-C00152.png)
US10774065B2 (en) 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
EP3094629B1 (en) 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
EP3724178B1 (en) 1-(piperidinocarbonylmethyl)-2-oxopiperazine derivatives for treating cancer
EP1490355B1 (en) Indolylmaleimide derivatives
JP4542783B2 (ja) スルホンアミド含有複素環化合物及び血管新生抑制剤とを組み合わせてなる抗腫瘍剤
JP6021805B2 (ja) 腫瘍治療剤
JP2007529421A5 (US07794700-20100914-C00152.png)
US20060025420A1 (en) Pharmaceutical compositions for the treatment of female sexual disorders
JP7458336B2 (ja) γcサイトカイン活性の調節
US20080207572A1 (en) Use of Dual C-Kit/Fgfr3 Inhibitors for Treating Multiple Myeloma
JP2010509356A5 (US07794700-20100914-C00152.png)
JP2006507265A5 (US07794700-20100914-C00152.png)
JP2003500404A5 (US07794700-20100914-C00152.png)
JP2011511075A5 (US07794700-20100914-C00152.png)
RU2007106933A (ru) Ингибиторы hsp90
US20160184383A1 (en) Method of treating cancer
RU2002111866A (ru) Производные N-замещенного индол-3-глиоксиламида - противоопухолевое лекарственное средство и средство, подавляющее ангиогенез (варианты), фармацевтическая композиция и противоопухолевое лекарственное средство (варианты)
JP2005526794A5 (ja) ベンズイミダゾールおよびマイトジェン活性化およびrhoキナーゼ阻害剤としてのその使用
JP2021501756A5 (US07794700-20100914-C00152.png)
JP2003519137A5 (US07794700-20100914-C00152.png)
JP2017525717A5 (US07794700-20100914-C00152.png)
RU2011121354A (ru) Синтетические миметики иммунной защиты и их применение
JP2002523496A5 (US07794700-20100914-C00152.png)
JP2014521620A5 (US07794700-20100914-C00152.png)